Anterix Inc

ATEX has undergone a decisive support failure within its Stage 2 advance, invalidating the prior medium-term bullish bias and shifting to a bearish medium-term posture. Short-term price remains below the 9 EMA and 20 EMA with no reclaim or follow-through, making timing unfavorable. We will trim exposure into the short-term EMA area around the recent breakdown zone.

• ↑41% YoY revenue growth to $2M in Q4 2026, driven by spectrum deals.
• ↑$71M quarter gain from spectrum monetization; projected cash proceeds now $120M.
• ↓Negative earnings yield indicates challenges in delivering adequate returns.